منابع مشابه
FDA perspective on anti-TNF treatments.
Although there are many points I would like to make about the FDA’s perspective on antiTNF treatments, I have limited myself to those 10 that I believe are most important. I present several of these less as absolutes than as stimulants for discussion, as I wish to make use of the expertise at this conference for furthering our collective understanding of how anti-TNF agents might best be used.
متن کاملDo TNF-blockers reduce or induce uveitis?
Do TNF-blockers reduce or induce uveitis? SIR, Uveitis is a well-known manifestation of SpAs that may lead to functional impairment. TNF-blockers are effective for treating SpA-related uveitis flares [1], but recent retrospective studies support the possibility of differential TNF-blockers effectiveness, with infliximab or adalimumab showing a higher efficacy than etanercept in the treatment of...
متن کاملCNS Demyelination with TNF-α Blockers
Tumor necrosis factor-α (TNF-α) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- α blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side effects associated with immune suppression have been reported, including central and peripheral ...
متن کاملBis-quaternary ammonium blockers as structural probes of the sarcoplasmic reticulum K+ channel
A series of n-alkyl-bis-alpha,omega-trimethylammonium (bisQn) compounds was synthesized, and their ability to block K+ currents through a K+ channel from sarcoplasmic reticulum was studied. K+ channels were inserted into planar phospholipid membranes, and single-channel K+ currents were measured in the presence of the blocking cations. These bisQn compounds block K+ currents only from the side ...
متن کاملEfficacy of TNF blockers from the perspective of growth velocity: slovak experience
Methods 34 patients (17 girls, 17 boys) with DMARDs-resistant polyarticular JIA receiving TNFa blocker (28 etanercept, 6 adalimumab) + methotrexate were evaluated during their first year of biologic therapy. The mean age at antiTNF treatment initiation was 10.52 (range 2.98-17.77). Median duration of disease was 4.42 years (range 0.8910.63), 24 patients received corticosteroids. Control group, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 2008
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0808-845b